drugset / Trial / NCT01363648

The Efficacy of Gliatiline® on Post-stroke Patients With Vascular Cognitive Impairment no Dementia

NCT01363648

Phase 4 Completed 222 enrolled Seoul National University Hospital
RandomizedParallel-groupQuadruple-blindTreatment

Summary

To date, there are no approved treatments for vascular cognitive impairment (VCI) and the main therapeutic efforts are aimed at controlling vascular risk factors for countering VCI development or progression. Several studies have reported cholinergic deficits in brain and cerebrospinal fluid of patients with VCI. The effect of choline alphoscerate in clinical studies of Alzheimer's disease and VCI improved memory and attention impairments. The purpose of our study is to determine effectiveness of choline alphoscerate vs placebo in improving cognition in post-stroke patients with VCI-non dementia (VCI-ND).

Timeline

Start
2010-11
Primary completion
2013-03
Completion
2013-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Choline Alfoscerate Unknown 400 mg